The announcement of Landos Biopharma presenting new data at a major congress is likely to be viewed positively by investors, as it demonstrates progress in the company's research and development efforts. The focus on NX-13, which is in a Phase 2 trial, could raise expectations for the drug's potential, possibly leading to increased investor interest and a positive short-term impact on the stock price. However, the actual impact will depend on the market's perception of the presented data and the overall progress of the clinical trial.